NCT01449058 - A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors | Biotech Hunter

Enrollment

139

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

August 15, 2017

Conditions

Advanced and Selected Solid TumorsAMLHigh Risk and Very High Risk MDS

Interventions

DRUG

BYL719

taken orally

DRUG

MEK162

taken orally

Trial Locations (16)

3050

Array BioPharma Investigative Site, Parkville

6500

Array BioPharma Investigative Site, Bellinzona

10461

Montefiore Medical Center SC, The Bronx

20133

Array BioPharma Investigative Site, Milan

33612

H. Lee Moffitt Cancer Center & Research Institute H. Lee Moffitt SC, Tampa

60611

Northwestern Memorial Hospital, Chicago

84103

University of Utah / Huntsman Cancer Institute Huntsman (3), Salt Lake City

90033

Memorial Sloan Kettering Cancer Center Onc. Dept, New York

94805

Array BioPharma Investigative Site, Villejuif

92093-0658

University of California San Diego - Moores Cancer Center Dept Onc, La Jolla

02114

Massachusetts General Hospital CCPO, Boston

77030-4009

University of Texas/MD Anderson Cancer Center Dept. of Onc., Houston

00168

Array BioPharma Investigative Site, Roma

08035

Array BioPharma Investigative Site, Barcelona

08036

Array BioPharma Investigative Site, Barcelona

SM2 5PT

Array BioPharma Investigative Site, Sutton